Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Simulations Plus, Inc. - Common Stock (NQ: SLP )

28.58 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Simulations Plus, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
Stable Payouts, Increasing Performance: Simulations Plus Supports Investors with Growing Earnings
Via Benzinga
Simulations Plus to Host Investor Day on Tuesday, November 14th
From Simulations Plus, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Simulations Plus Reports Fourth Quarter and Fiscal 2023 Financial Results
From Simulations Plus, Inc.
Via Business Wire
Earnings Scheduled For October 25, 2023
Companies Reporting Before The Bell • Deutsche Bank (NYSE:DB) is estimated to report quarterly earnings at $0.52 per share on revenue of $7.65 billion. 
Via Benzinga
Simulations Plus Earnings Preview
Via Benzinga
Recap: Simulations Plus Q3 Earnings
Via Benzinga
Simulations Plus's Earnings: A Preview
Via Benzinga
Why Harley-Davidson Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers 
Via Benzinga
Simulations Plus Announces Fourth Quarter and Fiscal Year 2023 Earnings Release and Conference Call
From Simulations Plus, Inc.
Via Business Wire
Preview: Simulations Plus's Earnings
Via Benzinga
Simulations Plus Receives New FDA Grant Award
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Hosts First-of-its-Kind Virtual Summer Camp for Students and Professors
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Chief Science Officer Dr. Viera Lukacova Honored as Fellow by the American Association of Pharmaceutical Scientists (AAPS)
From Simulations Plus, Inc.
Via Business Wire
Researchers Use the Simulations Plus DILIsym® Platform to Predict Safety of Combined CBD and VPA Treatment
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Releases ADMET Predictor® 11
From Simulations Plus, Inc.
Via Business Wire
Simulations An Attractive Vehicle For Investors Seeking Exposure To Biotech Innovation Themes, Analyst Says
Oppenheimer analyst Francois Brisebois reiterated an Outperform rating on Simulations Plus, Inc. (NASDAQ: SLP) with a  
Via Benzinga
Costco, AZZ And 3 Stocks To Watch Heading Into Friday
With U.S. stock futures trading slightly lower this morning on Friday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
Simulations Plus Reports Third Quarter Fiscal 2023 Financial Results
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Announces Third Quarter Fiscal Year 2023 Earnings and Conference Call Date
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Is High-Growth Investment Opportunity In The Wake Of Immunetrics Acquisition: Analyst
Oppenheimer analyst Francois Brisebois reiterated an Outperform rating on the shares of Simulations Plus, Inc. (NASDAQ: SLP),  
Via Benzinga
Simulations Plus Acquires Immunetrics to Expand its Immunology and Oncology Drug Development Capabilities
From Simulations Plus, Inc.
Via Business Wire
7 Stocks Under $50 to Buy (and Never Sell)
Although you usually get what you pay for, these best affordable stocks to invest in punch above their weight class. 
Via InvestorPlace
Simulations Plus Launches New Integrated Pulmonary Software and Services Package to Streamline Drug Development and Improve Patient Outcomes
From Simulations Plus, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For May 9, 2023
Via Benzinga
Roblox And 3 Other Stocks Insiders Are Selling
The Nasdaq Composite closed sharply higher on Thursday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
Simulations Plus Receives U.S. FDA Renewal for DILIsym Software Licenses
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Reports Second Quarter Fiscal 2023 Financial Results
From Simulations Plus, Inc.
Via Business Wire
MIDD+ 2023 Panelists Discuss How to Increase Gender Equity for Women in Science
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Enters New Strategic Collaboration to Discover Anticancer Therapies Through Its AI-Driven Drug Design Technology
From Simulations Plus, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.